Published in Z Gastroenterol on January 05, 2012
Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int (2012) 1.60
Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol (2014) 0.95
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol (2014) 0.94
Current status in the therapy of liver diseases. Int J Mol Sci (2014) 0.87
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One (2014) 0.84
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One (2014) 0.81
Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. PLoS One (2013) 0.80
Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS One (2016) 0.80
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. Biomed Res Int (2013) 0.78
The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Viszeralmedizin (2015) 0.77
Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors. PLoS One (2016) 0.75
Successful antiviral triple therapy in a longstanding refractory hepatitis C virus infection with an acute kidney injury. Case Rep Nephrol (2014) 0.75
Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS One (2016) 0.75
Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. Am J Case Rep (2016) 0.75
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 7.89
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science (1989) 4.08
Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther (2014) 3.91
EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V. Mol Microbiol (1997) 3.75
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Typing of intimin genes in human and animal enterohemorrhagic and enteropathogenic Escherichia coli: characterization of a new intimin variant. Infect Immun (2000) 3.66
Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 3.59
Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology (1997) 3.52
The chromodomain protein Swi6: a key component at fission yeast centromeres. Science (1995) 3.40
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 3.30
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem (1993) 3.23
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
Relation between directly detected patent foramen ovale and ischemic brain lesions in sport divers. Ann Intern Med (2001) 2.92
Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg (1983) 2.91
Selective targeting of somatostatin receptor 3 to neuronal cilia. Neuroscience (1999) 2.84
IgE concentrations in children with atopic diseases. A clinical study. Int Arch Allergy Appl Immunol (1969) 2.84
Illusory conjunctions in the perception of objects. Cogn Psychol (1982) 2.78
Genetic diversity of intimin genes of attaching and effacing Escherichia coli strains. J Clin Microbiol (2002) 2.62
KatP, a novel catalase-peroxidase encoded by the large plasmid of enterohaemorrhagic Escherichia coli O157:H7. Microbiology (1996) 2.53
Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut (2006) 2.53
Spectinomycin hydrochloride (Trobicin) in the treatment of gonorrhoea. Observation of resistant strains of Neisseria gonorrhoeae. Br J Vener Dis (1973) 2.53
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 2.47
Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell (1999) 2.45
Isolation and characterization of rat liver amphisomes. Evidence for fusion of autophagosomes with both early and late endosomes. J Biol Chem (1998) 2.44
Predicting acute maxillary sinusitis in a general practice population. BMJ (1995) 2.44
Clonal structure and pathogenicity of Shiga-like toxin-producing, sorbitol-fermenting Escherichia coli O157:H-. J Clin Microbiol (1993) 2.43
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet (2001) 2.40
Transport and storage of vitamin A. Science (1990) 2.39
Endoscopic transhiatal drainage of a mediastinal pancreatic pseudocyst. Endoscopy (2004) 2.34
Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict (1999) 2.34
Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat (2003) 2.33
Do gender differences exist in pacemaker implantation?--results of an obligatory external quality control program. Europace (2009) 2.30
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat (2011) 2.30
Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes. Biochim Biophys Acta (1977) 2.28
Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology (2005) 2.24
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther (2013) 2.21
Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Aliment Pharmacol Ther (2014) 2.18
[Non-surgical removal of a knotted Swan-Ganz catheter]. Anaesthesist (1991) 2.16
Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 2.12
Hereditary hemorrhagic telangiectasia: effective protocol for embolization of hepatic vascular malformations--experience in five patients. Radiology (1998) 2.12
ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr (2006) 2.11
Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J Med Microbiol (1994) 2.08
Testing the porphyrinogenicity of propofol in a primed rat model. Br J Anaesth (1995) 2.08
AmpG, a signal transducer in chromosomal beta-lactamase induction. Mol Microbiol (1993) 2.06
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors. Ann Intern Med (1999) 2.05
Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther (2013) 2.04
Long-term shedding and clonal turnover of enterohemorrhagic Escherichia coli O157 in diarrheal diseases. J Clin Microbiol (1995) 2.04
Ultrastructural and immunocytochemical characterization of autophagic vacuoles in isolated hepatocytes: effects of vinblastine and asparagine on vacuole distributions. Exp Cell Res (1995) 2.03
Postcremation diagnosis from an electric shaver. Lancet (2001) 2.02
Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet (1991) 2.02
Structural analysis of phage-borne stx genes and their flanking sequences in shiga toxin-producing Escherichia coli and Shigella dysenteriae type 1 strains. Infect Immun (2000) 2.01
Nucleotide sequence analysis of enteropathogenic Escherichia coli (EPEC) adherence factor probe and development of PCR for rapid detection of EPEC harboring virulence plasmids. J Clin Microbiol (1994) 2.01
[Magnet resonance imaging in common injuries of the wrist]. Unfallchirurg (2014) 2.01
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
The large plasmids of Shiga-toxin-producing Escherichia coli (STEC) are highly variable genetic elements. Microbiology (1999) 1.97
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut (2001) 1.97
[Investigations of the penicillin concentration in the serum following benzyl penicillin sodium in massive doses. With reference to the treatment of gonorrhea in Greenland]. Ugeskr Laeger (1965) 1.96
Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol (2010) 1.95
The fission yeast rad22 gene, having a function in mating-type switching and repair of DNA damages, encodes a protein homolog to Rad52 of Saccharomyces cerevisiae. Nucleic Acids Res (1993) 1.94
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 1.92
Asymmetry pays: visual lateralization improves discrimination success in pigeons. Curr Biol (2000) 1.92
Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int (2006) 1.91
Molecular characteristics and epidemiological significance of Shiga toxin-producing Escherichia coli O26 strains. J Clin Microbiol (2000) 1.90
Molecular characterization of the lincomycin-production gene cluster of Streptomyces lincolnensis 78-11. Mol Microbiol (1995) 1.89
High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology (1995) 1.88
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
A genomic island, termed high-pathogenicity island, is present in certain non-O157 Shiga toxin-producing Escherichia coli clonal lineages. Infect Immun (1999) 1.86
Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A (1988) 1.86
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther (2011) 1.85
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology (1998) 1.84
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med (2008) 1.84
Enteroaggregative, Shiga toxin-producing Escherichia coli O111:H2 associated with an outbreak of hemolytic-uremic syndrome. J Clin Microbiol (1998) 1.83